ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tigulixostat

Also written as “Tigulixostat”, “LC350189 formulated capsule” and “IBI128”.

Its studies are mostly in Gout · Hyperuricemia, led by 2 companies.

Drug pageTigulixostat: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 16, 202210 company-led studies, 1 open or runningNext primary completion: Apr 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
LG Chem80 open or runningphase 3since Oct 16, 2022May 19, 2011none ahead
Innovent Biologicsits history only21 open or runningphase 3since Feb 3, 2026Jul 2, 2024Apr 30, 2027phase 3 · NCT07414394

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of LG Chem only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. May 19, 2011First study: phase 1 study in HyperuricemiaFirst studyNCT01361646 · 129 enrolled · Korea, Republic of
  2. Apr 25, 2019Phase 2 study in GoutNCT03934099 · 156 enrolled · United States
  3. Aug 19, 20192 phase 1 studies in GoutNCT04070846, NCT04066712
  4. Dec 19, 2020Named tigulixostatINNProposed as its International Nonproprietary Name in WHO's List 124 · before, IBI128
  5. Jun 28, 2021Early phase 1 study in HyperuricemiaNCT04966325 · 37 enrolled · United States
  6. Oct 16, 20222 phase 3 studies in GoutNCT05586971, NCT05586958
  7. Dec 7, 2023Phase 1 study in GoutNCT06189404 · 24 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 LG Chem leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06189404Gout · United States1CompletedNov 13, 202324
NCT05586971Gout · United States, Argentina, Australia and more3CompletedMay 6, 20252,202
NCT05586958Gout · United States, Georgia, Philippines and more3CompletedNov 4, 2024354
NCT04966325Hyperuricemia · United StatesEarly 1CompletedDec 7, 202137
NCT04066712Gout · United States1CompletedSep 12, 202037
NCT04070846Gout · United States1CompletedMar 7, 20206
NCT03934099Gout · United States2CompletedMay 3, 2021156
NCT01361646Hyperuricemia · Korea, Republic of1CompletedJan 2013129

How it is read

Names in the registry

  • “Tigulixostat”, 4 entries
  • “LC350189 formulated capsule”, 1 entry
  • “IBI128”, 1 entry
  • “LC350189 200mg”, 1 entry
  • “LC350189 600mg”, 1 entry

Codes read as this program: IBI128.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.